Know Cancer

or
forgot password

Glucosamine and Chondroitin Effects


N/A
20 Years
55 Years
Open (Enrolling)
Both
Inflammation

Thank you

Trial Information

Glucosamine and Chondroitin Effects


Use of glucosamine and chondroitin have been associated with reduced cancer and overall
mortality. The aim of this study is to determine whether a common starting dose of
glucosamine and chondroitin (1500 mg/d + 1200 mg/d, respectively) reduces systemic
inflammation as reflected by a reduction in high sensitivity C-reactive protein.


Inclusion Criteria:



- Healthy

- Overweight (body mass index kg/m2 (BMI) between 25 and 32.5)

- Non-smoking men and women

- Aged 20-55y

Exclusion Criteria:

- Chronic medical illness, history of gastrointestinal, hepatic, or renal disorders, or
inflammatory conditions (including autoimmune and inflammatory diseases)

- Pregnancy or lactation

- Currently on a weight-loss diet

- BMI (body mass index) < 25 or > 30

- Alcohol intake of greater than 2 drinks/day

- Current use of prescription or over-the-counter medications, (Excluding oral
contraceptives and hormone-secreting IUDs), including use of aspirin or NSAIDs more
than 2 days per week

- Abnormal renal, liver or metabolic test

- Inability to swallow pills

- Known allergy to shellfish

- Not willing to take pills made from shellfish or animal sources

- Intention to relocate out of study area within next 4 months

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Outcome Measure:

hsCRP

Outcome Description:

hsCRP is a biomarker of systemic inflammation

Outcome Time Frame:

1 year

Safety Issue:

No

Authority:

United States: Institutional Review Board

Study ID:

7798

NCT ID:

NCT01682694

Start Date:

September 2012

Completion Date:

August 2013

Related Keywords:

  • Inflammation
  • Inflammation

Name

Location

Fred Hutchinson Cancer Research CenterSeattle, Washington  98109